Stockscreener 앱 받기
34.02
1.37%
0.46
시장 영업 전:
34.08
0.06
+0.18%
전일 마감가:
$33.56
열려 있는:
$33.77
하루 거래량:
845.83K
Relative Volume:
0.76
시가총액:
$2.98B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-15.53
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
-5.16%
1개월 성능:
+6.48%
6개월 성능:
+52.69%
1년 성능:
+31.96%
1일 변동 폭
$33.12
$34.25
1주일 범위
$33.12
$37.08
52주 변동 폭
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
34.02 | 2.94B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial - Yahoo Finance
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com India
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com Australia
IDEAYA Biosciences (NASDAQ: IDYA) wraps mUM 2/3 enrollment, PFS in 1Q 2026 - Stock Titan
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
IDEAYA Biosciences submits IND for novel cancer drug IDE574 - Investing.com India
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView — Track All Markets
IDEAYA Biosciences (Nasdaq: IDYA) submits IND for IDE574, a KAT6/7 inhibitor in breast and lung cancer - Stock Titan
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week HighHere's Why - MarketBeat
Federated Hermes Inc. Has $97.27 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
GSK ends collaboration with IDEAYA for two candidates - MSN
Can IDEAYA Biosciences Stock Hold Up When Markets Turn? - Trefis
IDEAYA Biosciences, Inc. $IDYA Stock Holdings Lifted by New York State Common Retirement Fund - MarketBeat
Schroder Investment Management Group Has $4.64 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Why IDEAYA Biosciences Shares Are Under Pressure - TipRanks
GlaxoSmithKline to end collaboration with Ideaya Biosciences on two clinical programs - Investing.com Nigeria
IDEAYA Biosciences Shares Climb After FDA Clears Bispecific ADC Candidate - MSN
IDEAYA Biosciences Receives Termination Notice from GSK - TradingView — Track All Markets
Ideaya Biosciences stock hits 52-week high at 36.57 USD By Investing.com - Investing.com Nigeria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire India
Will IDEAYA Biosciences Inc. (30J) stock profit from automation wave2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance - marketscreener.com
IDEAYA Biosciences (Nasdaq: IDYA) gets FDA IND for IDE034 Phase 1 solid tumor study - Stock Titan
How big funds are accumulating IDEAYA Biosciences Inc. (30J) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - Newser
Ideaya Biosciences stock hits 52-week high at 36.57 USD - Investing.com
IDEAYA Biosciences, Inc. $IDYA Stock Position Reduced by Fisher Asset Management LLC - MarketBeat
Is IDEAYA Biosciences Inc. (30J) stock a fit for income portfoliosGDP Growth & Weekly Top Gainers Trade List - Newser
Is IDEAYA Biosciences Inc. (30J) stock safe for risk averse investors2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week HighTime to Buy? - MarketBeat
Transcript : IDEAYA Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09 - marketscreener.com
Can IDEAYA Biosciences Inc. stock beat market expectations this quarter2025 Top Gainers & High Yield Stock Recommendations - Newser
Can IDEAYA Biosciences Inc. stock beat analyst upgradesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Will IDEAYA Biosciences Inc. (30J) stock hit analyst forecastsTrade Ideas & Daily Profit Maximizing Tips - Newser
IDEAYA receives FDA approval to begin IDE034 clinical trial - Yahoo
Is IDEAYA Biosciences Inc. (30J) stock good for wealth creation2025 Big Picture & Technical Buy Zone Confirmation - Newser
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Citi Global Healthcare Conference - marketscreener.com
Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types - marketscreener.com
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):